Manson Publishing, Sep 2010, Pages: 160
As the series title implies each Clinician’s Desk Reference will be a practical resource and a daily aid for physicians in the hospital setting and in primary care.
Asthma is one of the most
Timely Data Resources, Inc., June 2011, Pages: 17
The Asthma Executive Market Summary 2011 provides an overview of the disease and related conditions, with incidence and prevalence numbers and percentages for major countries worldwide, information
Sociable Pharma, Oct 2011, Pages: 92
Society's 2011 Annual Congress, opinion was gauged on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by asthma specialists.
Understand key
Datamonitor, Sep 2010
Introduction
This model contains a 10 year country, indication, and device specific forecasts for individual products used in asthma and COPD, taking into account competitive positioning and key
Draco Healthcare Consulting LLC, May 2009, Pages: 103
According to the 2004 Global Burden of Asthma Report, there were about 300 million asthma patients worldwide. One out of every 250 disease-related deaths was caused by asthma. In China
AMID Co., June 2009, Pages: 259
Chinas demand for Asthma Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines Chinas
Business Insights, May 2011, Pages: 81
in the respiratory market over the period 2010–16.
Highlights
The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment
GlobalData, Aug 2011, Pages: 111
Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Asthma Therapeutics - Pipeline Assessment
IMS Health, Jan 2007, Pages: 293
, Japan, Mexico, Spain, the UK and the USA. We then conclude the report with a highly inclusive analysis of the markets future growth potential. Executive Summary
Anti asthma/ COPD Products Key
GlobalData, Dec 2010, Pages: 66
“Asthma - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Asthma market. The report identifies the key trends shaping
Frost & Sullivan, April 2011, Pages: 114
This research service provides an in depth analysis of factors affecting the growth of the U.S. asthma/COPD market over the period 2006-2016. Included is a disease overview, product analysis, total
Clinical Publishing, June 2007, Pages: 144
Asthma currently affects more than 150 million people worldwide with almost half of these experiencing symptoms that disrupt their everyday lives. In addition prevalence is rapidly increasing
Informa Healthcare, Jan 2007, Pages: 388
There is growing interest in the pronounced variability in the incidence and severity of chronic respiratory diseases such as Asthma, observed to occur in any particular patient over a given period
Clinical Publishing, Jan 2007, Pages: 220
The care of an increasing number of adult and child patients with asthma has become a major task for clinicians, and a growing concern for public health physicians and health care administrators
Frost & Sullivan, July 2007, Pages: 82
This Frost & Sullivan research service titled European Asthma Therapeutics Markets provides key challenges, forecasts and recommendations for the asthma therapeutics market. In this research, Frost
GBI Research, Nov 2011, Pages: 76
GBI Research’s report, “Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD”, provides an in-depth analysis of patient recruitment scenario
Elsevier Science and Technology, Nov 2008, Pages: 896
The Second Edition of Asthma and COPD: Basic Mechanisms and Clinical Management continues to provide a unique and authoritative comparison of asthma and COPD. Written and edited by the world
Global Industry Analysts, Inc., Oct 2006, Pages: 383
This report analyzes the worldwide markets for Asthma Therapeutics in US$ Million. The major therapeutic segments analyzed are Inhaled corticosteroids, Short acting beta agonists, Long acting beta
Datamonitor, June 2009
.
Key reasons to purchase this title
- Identify key opportunities and threats that will impact the use and uptake of new and existing products
- Quantify the future size and scope of the asthma/COPD
John Wiley and Sons Ltd, April 2010, Pages: 104
Asthma is a common condition with increasing prevalence. This new edition of the highly regarded ABC of Asthma has been thoroughly revised with reference to the latest British Thoracic Society
